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Abstract
Streptococcal pharyngitis is a very common pathology in paediatric age all over the world. Nevertheless there isn’t
a joint agreement on the management of this condition. Some authors recommend to perform a microbiological
investigation in suspected bacterial cases in order to treat the confirmed cases with antibiotics so to prevent
suppurative complications and acute rheumatic fever. Differently, other authors consider pharyngitis, even
streptococcal one, a benign, self-limiting disease. Consequently they wouldn’t routinely perform microbiological
tests and, pointing to a judicious use of antibiotics, they would reserve antimicrobial treatment to well-selected
cases. It has been calculated that the number of patients needed to treat to prevent one complication after upper
respiratory tract infections (including sore throat), was over 4000.
Even the use of the Centor score, in order to evaluate the risk of streptococcal infection, is under debate and the
interpretation of the test results may vary considerably. Penicillin is considered all over the world as first line
treatment, but oral amoxicillin is also accepted and, due to its better palatability, can be a suitable option.
Macrolides should be reserved to the rare cases of proved allergy to b-lactams. Cephalosporins can be used in
patients allergic to penicillin (with the exception of type I hypersensibility) and have been also proposed to treat
the relapses.
Introduction
Acute pharyngitis is defined as an infection of the phar-
ynx and/or tonsils. It is a very common pathology
among children and adolescents. Although viruses cause
most acute pharyngitis episodes, group A Streptococcus
(GABHS) causes 37% of cases of acute pharyngitis in
children older than 5 years [1]. Other bacterial causes of
pharyngitis are Group C Streptococcus (5% of total
cases), C. pneumoniae (1%), M. pneumoniae (1%) and
anaerobic species (1%). Between viruses Rhinovirus,
Coronavirus and Adenovirus account for the 30% of the
total cases, Epstein Barr virus for 1%, Influenza and
Parainfluenza virus for about 4% [2].
Streptococcal pharyngitis has a peak incidence in the
early school years and it is uncommon before 3 years of
age. Illness occurs most often in winter and spring [3].
The infection is transmitted via respiratory secretions
and the incubation period is 2-5 days. Communicability
of the infection is highest during acute phase and in
untreated people gradually diminishes over a period of
weeks; it ceases after 24 hours of antibiotic therapy [4].
Clinical manifestations include sore throat and fever
with sudden onset, red pharynx, enlarged tonsils covered
with a yellow, blood-tinged exudate. There may be pete-
chiae on the soft palate and posterior pharynx. The
anterior cervical nodes are enlarged and swollen. Head-
ache and gastrointestinal symptoms (vomiting and
abdominal pain) are frequent. Table 1 shows signs and
symptoms of GABHS pharyngitis and their sensitivity
and specificity for the diagnosis [5].
The onset of viral pharyngitis may be more gradual
and symptoms more often include rhinorrhea, cough,
diarrhea, hoarseness. Several clinical scores have been
proposed to help the clinician in the diagnosis; they are
illustrated in table 2.
Anyway the clinical presentations of GABHS and viral
pharyngitis show considerable overlap and no single ele-
ment of the patient’s history or physical examination
reliably confirms or excludes GABHS pharyngitis [5].
Complications of the infection can be distinguished in
suppurative and nonsuppurative. Suppurative complica-
tions, due to the spread of GABHS to adjacent tissues,
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include cervical lymphadenitis, peritonsillar abscess, ret-
ropharyngeal abscess, otitis media, mastoiditis and sinusi-
tis. The use of antibiotics have reduced the incidence of
this group of complications, that remain a reality when
primary illness has gone unnoticed or untreated [3].
Not suppurative, immune-mediated sequelae are acute
rheumatic fever (ARF), acute post-streptococcal glomer-
ulonephritis, Sydenham chorea, reactive arthritis and
Paediatric Autoimmune Neuropsychiatric Disorders
Associated with Streptococcus pyogenes.
According to WHO, at least 15.6 million people have
rheumatic hearth disease (RHD), and 233 000 deaths
annually are directly attributable to ARF. Due to the
limitations of reports related to limited resources in
developing countries, it is likely that the prevalence and
incidence of ARF are largely underestimated [6].
The prevalence of RHD in children aged 5-14 years is
higher in sub-Saharan Africa (5.7 per 1000), in Indigen-
ous populations of Australia and New Zealand (3.5 per
1000), and southcentral Asia (2.2 per 1000), and lower
in developed countries (usually 0.5 per 1000) [7].
A systematic review of 10 population-based studies
from 10 countries on all continents, except Africa, pub-
lished from 1967 to 1996, describes the worldwide inci-
dence of ARF. The overall mean incidence rate of first
attack of ARF was 5-51/100,000 population (mean 19/
100,000; 95% CI 9 to 30/100,000). A low incidence rate
of ≤10/100,000 per year was found in America and Wes-
tern Europe, while a higher incidence (> 10/100,000) was
documented in Eastern Europe, Middle East (highest),
Asia and Australasia. Studies with longitudinal data dis-
played a falling incidence rate over time [8].
In the United States, the number of ARF cases
has fallen dramatically over the last half century.
A national study conducted in 2000 detailing the charac-
teristics of American pediatric patients hospitalized with
ARF found that the incidence was 14.8 cases per 100,000
hospitalized children (though the true national incidence
of ARF cases is 1 case per 100,000 population) [9].
The diagnosis of GABHS pharyngitis can be done by a
throat culture or rapid diagnostic test for GABHS
(RADT). The culture is the gold standard for diagnosis
but requires 18-24 hours of incubation at 37°C, causing a
delay in identification of GABHS. This delay in diagnosis
often leads physicians to administer therapy without first
knowing the etiological agent, causing an overuse of anti-
biotics that provokes a rising in the diffusion of drug-
resistant bacterial strains. RADTs allow the identification
of GABHS on a throat swab in a matter of minutes. This
strategy has a significant impact on reducing the antibio-
tic prescription [10]. The tests are based on nitrous acid
extraction of group A carbohydrate antigen from organ-
isms obtained by throat swab. The specificities of RADTs
are generally high while sensitivities vary considerably
[4]. Rapid tests offer good accuracy for use as diagnostic
method, however, in some situations, they have to be
complemented with the microbiological culture, because
of the possibility of false negative results [11]. Tanz et al
in a study including 1848 children from 3 to 18 years
evaluated for acute pharyngitis in 6 community pediatric
offices demonstrate that Rapid antigen-detection test
sensitivity was 70%. Office culture sensitivity was signifi-
cantly greater, 81%. Rapid antigen-detection test specifi-
city was 98%, and office culture specificity was 97%, a
difference that was not statistically significant [12].
Table 1 Clinical signs and symptoms of GABSH
pharingitis, their sensitivity and specificity [5]
Symptoms and Clinical Findings Sensitivity
(%)
Specificity
(%)
Absence of cough 51-79 36-68
Anterior cervical nodes swollen or
enlarged
55-82 34-73
Headache 48 50-80
Myalgia 49 60
Palatine petechiae 7 95
Pharyngeal exudates 26 88
Fever >38°C 22-58 52-92
Tonsillar exudate 36 85
Table 2 Clinical Score for GABSH pharyngitis
Reference Clinical signs and symptoms Sensibility
(%)
Specificity
(%)
[37] Recent exposure to GABHS, pharyngeal exudate, enlarged or tender cervical nodes, fever 55 74
[38] Season, age, white cells count, fever, absence of cough, enlarged cervical nodes, tonsillar exudate or
swelling
68 85
[39] Swollen and tender anterior cervical nodes, tonsillar exudate 84 40
[40] Fever, cervical nodes enlargement, tonsillar exudate or swelling or hypertrophy, Absence of cough 63 67
[41] Season, age, fever, enlarged cervical nodes, tonsillar exudate or swelling or hypertrophy, absence of cough
or rhinitis or conjunctivitis
22 93
[42] Tonsillar hypertrophy, enlarged cervical nodes, absence of rhinitis, scarlet fever rash 18 97
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Management
There is no joint agreement for the clinical management
of pharyngotonsillitis. Experts recommendations and
guidelines differ considerably regarding how to make
diagnosis, weather and when to treat. The many opi-
nions can be summarized in two position. One position,
espoused by American [4,13-15], French [16] and
Finnish [17] experts, considers GABHS pharyngitis an
infection that need to be recognised and treated to
avoid complications, first of all ARF. This implies the
recommendation to perform microbiological tests for
detecting the bacterial forms in order to treat them.
According to this position, in Italy a regional guideline
has been developed in Emilia Romagna [18]. The other
position, followed by UK [19], Scottish [20], Dutch [21]
and Belgian [22] authors, considers pharyngitis, even
GABHS one, a benign self limiting disease, given to the
low incidence of suppurative complications and ARF in
developed countries. This second idea leads to reserve
antibiotics treatment to selected cases, so as to make a
judicious use of antibiotics in order to avoid the spread
of resistant strains.
According to this position, a big retrospective cohort
study conduced by Petersen et al. in UK primary care
practices, on a total number of 3.36 million episodes of
respiratory tract infection, found out that the number of
patients needed to treat to prevent one complication
after upper respiratory tract infections (including sore
throat and otitis media), was over 4000. The study con-
cludes that antibiotics are not justified to reduce the
risk of serious complications for upper respiratory tract
infection, sore throat, or otitis media [23].
We are going to examine the different perspectives on
the management of pharyngitis in order to analyze sub-
stantial differences.
Diagnosis and indications to treat
With regard to diagnosis, major disputes concern the
use of microbiological tests (throat culture or RADT).
A clinical score proposed by Centor and subsequently
modified, considers the combination of signs and symp-
toms suggestive of GABHS pharyngitis and could help
clinician to address diagnosis [24]. Table 3 shows the
Centor score.
Anyway clinical of GABHS and viral pharyngitis can
be overlapped and no single element of the patient’s his-
tory or physical examination reliably confirms or
excludes GABHS pharyngitis [5]. The indication to
make diagnosis using the Centor score alone or in asso-
ciation with microbiological tests varies widely all over
the world.
English experts in NICE guidelines state that, depend-
ing on clinical assessment of severity, patients presenting
acute pharyngitis can be considered for an immediate
antibiotic prescribing strategy (in addition to a no anti-
biotic or a delayed antibiotic prescribing strategy) if three
or more Centor criteria are present. Otherwise if Centor
≤ 2, no further investigations and no treatment are
required [19]. UK guidelines reserve an immediate anti-
biotic prescription or further investigations to the situa-
tions in which the patient is systemically very unwell, has
symptoms and signs suggestive of serious illness or sup-
purative complications, or when a pre-existing comorbid-
ity (significant heart, lung, renal, liver or neuromuscular
disease, immunosuppression, cystic fibrosis, and young
children who were born prematurely) is present [19]. Fig-
ure 1 shows the flow chart of UK guideline (NICE guide-
line) [19]. Equally Scottish authors suggest that neither
throat swabs nor rapid antigen testing should be carried
out routinely in sore throat even if clinical examination is
not considered reliable upon to differentiate between
viral and bacterial etiology. Scottish experts consider that
the prevention of suppurative complications and ARF is
not a specific indication for antibiotic therapy in pharyn-
gitis [20].
On the other hand, most of the American authors sug-
gest the necessity of a microbiological confirmation for
the diagnosis of GABHS; clinical criteria can help clini-
cian to select patients who need to be tested [4,13-15].
Bisno et al, in the Infectious Diseases Society of
America (IDSA) guidelines, state to identify patients
Table 3 Centor Score [24]
Clinical criteria Points
Absence of cough 1
Swollen and tender anterior cervical nodes 1
Temperature > 38°C 1
Tonsillar exudate or swelling 1
Age 3 to 14 years 1
Age 15 to 44 years 0
Age 45 years and older -1
Centor  
Score < 1 Score = 1 Score = 
Risk 
10-17%
Risk 
<10%
No investigations
No treatment
 score
2 Score = 3 Score ? 4
Risk
52-53%
Risk 
28-35%
Antibiotic treatment 
can be considered 
Figure 1 NICE guideline: flow-chart for management of
pharyngitis [19].
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who may have GABHS pharyngitis considering clinical
and epidemiological features. If clinical and epidemiolo-
gical features suggest the possibility of GABHS infection,
a laboratory test (culture or RADT) should be per-
formed and, in case of positivity, antibacterial treatment
should be prescribed to the patient [14]. Figure 2 shows
the flow chart recommended by Bisno et al in IDSA
guidelines [14]. Snow et al, in the American College of
Physicians (ACP) guidelines, suggest the use of Centor
score to identify patients who may have GABHS phar-
yngitis. If Centor score is ≥ 2, then a microbiological
test should be performed. Adult patients with a Centor
score ≥ 4 should be treated without needing microbiolo-
gical confirmation [15]. The flow chart suggested by
Snow et al in ACP guidelines is illustrated in figure 3
[15]. However, it has been argued that this latter
approach would result in an over-treatment since only
50% of patients with a Centor score of 4 suffer from a
streptococcal pharyngitis [25].
Gerber et al in the scientific statement from the
American Heart Association, suggest to screen patients
with clinical and epidemiological criteria and to perform
RADT or throat culture in all patients with risk [13].
Focusing on pediatrics, American Academy of Pedia-
trics recommends to obtain a laboratory confirmation of
the presence of GABHS. In the decision to obtain a
throat swab specimen, the clinician has to consider the
age >3 years, clinical signs and symptoms of pharyngitis,
the season and the community epidemiology, including
contacts with GABHS infection or presence in the
family of a person with a history of ARF or poststrepto-
coccal glomerulonephritis. Children with signs or symp-
toms suggesting viral infection (coryza, conjunctivitis,
hoarseness, cough, stomatitis or diarrhea) should not be
tested [4].
Regarding the need to confirm a RADT negative
result, Snow and Bisno suggest to perform a throat cul-
ture in children, while no other investigation is indicated
in adults [14,15]. In reverse Gerber et al state that, if
RADT is negative, a throat culture should be performed
in both adults and children [13]. The need to confirm
negative RADT results with a throat culture is advised
also by American Academy of Pediatrics [4]. On the
contrary, because of the high specificity, it is not neces-
sary to confirm a positive RADT test [3].
It has been reported that RADTs are underused com-
pared to the indications given in the American guide-
lines. A big retrospective USA study conducted by Linder
et al including a total number of 4158 children with
pharyngitis aged 3-17 years shows that physicians per-
formed a GABHS test only in 63% of children with sore
throat and prescribed antibiotics to 53% of children,
exceeding the maximum expected prevalence of GABHS.
There was a significant difference in antibiotic prescrip-
tions between children who had a GABHS test performed
and those who did not: GABHS testing is associated with
a lower rate of antibiotic prescribing [26].
Considering Italy, the regional guideline of Emilia
Romagna suggests to perform a RADT when Centor
score ≥ 2. If RADT is positive then antibiotic treatment
should be started; if RADT is negative and the clinical
suspicion of GABHS pharyngitis is high, then a throat
culture should be performed. When Centor score is 5,
the physician should decide if starting the treatment
directly or performing a microbiological test [18]. This
flow chart is illustrated in figure 4 [18].
Treatment
As we explained before, antibiotic treatment is not rou-
tinely recommended, due to the prevalent viral etiology
of pharyngitis. However, when antimicrobial treatment
is indicated, it is important to choose a good therapeutic
option.
All the authors and national guidelines agree in sug-
gesting penicillin as first choice treatment, since GABHS
remains universally susceptible to penicillin [3].
Clinical and epidemiologic features
??????????????????
?????????????????
Negative
Performe a
throat culture
Positive
Antibiotic
treatment
No investigations
and no treatment
Performe a RADT
???????? ?????????????????
NegativeNo 
treatment
Figure 2 IDSA guideline: flow-chart for management of
pharyngitis [14].
Cen
Score < 1 Score = 1 Score = 
Risk < 10% Risk 10-17%
option
No investigations investigations
and no treatment Perform
*
 no treatment
Negative*If RADT is negative 
perform a throat 
culture in children
No treatment
tor Score
2 Score = 3 Score ? 4
Risk
52-53%
Risk 
28-35%
Antibiotic
treatment
 a RADT
Positive
Antibiotic 
treatment
Figure 3 ACP guideline: flow-chart for management of
pharyngitis [15].
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Although penicillin V is the drug of choice, ampicillin or
amoxicillin equally are effective and, due to the good
taste, represent a suitable option in children [4]. More-
over we have to remember that penicillin suspension is
not commercially available in several countries including
Italy, so that amoxicillin is usually prescribed.
Gerber et al state that prompt administration of peni-
cillin therapy shortens the clinical course, decreases the
incidence of suppurative sequelae, the risk of transmis-
sion and prevents ARF even when given up to 9 days
after illness onset [13].
Therapeutic options with doses and duration recom-
mended by American Academy of Pediatrics are illu-
strated in table 4 [3].
It is important to remember that macrolides are not
indicated in the treatment of pharyngitis, due to the
high rates of resistance to erythromycin among GABHS
in USA and Europe [27]. Indication for the use of
macrolides in pharyngitis is relegated to patients allergic
to b-lactam antibiotics. The allergy should be proved by
laboratory testing. If the patient’s hypersensitivity to
penicillin is not type I, cephalosporins should be consid-
ered a good therapeutic option [13].
The indication to use amoxicillin once daily, proposed
by Gerber et al and widely employed in USA, is not uni-
versally accepted. Amoxicillin given once daily is not
approved from Food and Drug Administration (FDA)
and European Medicines Agency (EMEA) for primary
profylaxis of ARF.
The standard duration of antibiotic therapy is 10 days.
It has been proposed to shorten it to 3-6 days, so to
improve the compliance [28]. A Cochrane review on 20
studies involving a total number of 13,102 cases of acute
GABHS has been published in 2009. The authors com-
pared short duration therapy (three to six days) of oral
antibiotics (all types included) to standard duration
treatment. They found that short duration treatment
presented lower risk of early clinical treatment failure
and no significant difference in early bacteriological
treatment failure, or late clinical recurrence. Anyway,
the overall risk of late bacteriological recurrence was
worse in short duration treatment, although no signifi-
cant differences were found when studies employing low
dose azithromycin (10 mg/kg) were eliminated. Authors
conclude that a short course (2 to 6 day) of oral antibio-
tics has an efficacy comparable to the standard duration
therapy in treating children with acute GABHS pharyngi-
tis [28]. Nevertheless the results of these review were lar-
gely criticized. Shad D.[29] underlines that at least one
more eligible trial [30] and one meta-analysis [31] were
not included. Besides, most of the trials included had
methodological inaccuracy (i.e. randomization was not
described or inappropriate in majority, only 3 of the 20
studies were blinded). Moreover ARF was considered as
main outcome only in 3 of the 20 included studies with a
total of 3 events recorded (insufficient power to make
conclusions) [29]. Fagalas et al in a recent meta-analysis
of Randomized Trials (8 RCTs, 1607 patients) found out
that short-course treatment for GABHS pharyngotonsilli-
tis is associated with inferior bacteriological eradication
rates [31]. After an adequate therapy, follow-up cultures
are not necessary unless symptoms recur [3].
Recurrent pharyngitis may represent a relapse or may
result from new exposure [3]. In case of relapse cepha-
losporins have been proposed to be more effective than
penicillin [32].
Some authors have suggested that cephalosporins
could have an efficacy higher than penicillin on GABHS
pharyngitis [33-35]. In a meta-analysis of 9 RCTs, invol-
ving 2113 adult patients with GABHS pharyngitis, Casey
and Pichichero indicate that the likelihood of a bacterio-
logic and clinical cure of GABHS tonsillopharyngitis in
adults is significantly higher after 10 days of therapy
with an oral cephalosporin than with oral penicillin.
They reported that the absolute difference in bacteriolo-
gic failure rates between cephalosporins and penicillin
was 5.4% [33]. They also conducted a meta-analysis of
RCT’s of cephalosporin versus penicillin treatment of
GABHS pharyngitis in children. It indicates that the
likelihood of bacteriologic and clinical failure is signifi-
cantly less if an oral cephalosporin is prescribed, com-
pared with oral penicillin [34].
Anyway it must be remembered that no guidelines
recommends cephalosporins as first choice drugs in the
treatment of GABHS pharyngitis because of the higher
cost compared to penicillin and the risk of selection of
resistant strains. Their recommendation in guidelines is
limited to patients with an hypersensibility to b-lactam
non I type [36].
Authors’ opinion and conclusion
Correct diagnosis and treatment of GABHS pharyngitis
are the key points to attain a judicious use of antibiotics,
Centor Score
Score ? 1 Score 2 - 4 Score = 5
Negative*
No treatment
Positive
Antibiotic
treatment
*If RADT is negative 
perform a throat 
culture when Centor
3-4 and clinical
suspicion of GABHS 
infection is high
No investigations
and no treatment Performe a RADT
Medical decision
Antibiotic
treatment
Perform
a RADT
Figure 4 Emilia Romagna regional guideline: flow-chart for
management of pharyngitis [18].
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and to prevent suppurative and non suppurative sequelae.
Thus, prudentially, we believe that paediatricians should
perform at least one microbiological test (RADT or throat
colture) in pharyngitis suspected for GABHS etiology, in
order to make the correct diagnosis. Most RADTs can
provide results in few minutes and their sensitivity is gen-
erally high [4]. Practically, we suggest that a negative
RADT should be confirmed by a throat culture only if
clinical suspicion of GABHS pharyngitis is high. Pharyngi-
tis of proved bacterial etiology should receive an antibiotic
treatment [4,13-15]. Penicillin V is the first choice drug,
but an oral suspension is not available in Italy. Amoxicillin
is equally effective and demonstrates higher palatability, so
that it can be used as first line therapy [4,15]. Macrolides
are not indicated in the treatment of GABHS pharyngitis
except for patients with a proved allergy to penicillin
(laboratory confirmation should be required) [4,15]. For
this group of patients Cephalosporins represent a good
alternative (left out cases of type I hypersensitivity to peni-
cillin) [4,15]. The inappropriate use of macrolides for
treatment of GABHS pharyngitis has been the main cause
of resistant strains diffusion in Western countries [27]. It
is important to underline that treatment duration should
be 10 days [4,15]. To improve the patient’s compliance the
physician should explain the importance of the complete
treatment (10 days) to eradicate the bacterium even if clin-
ical improvement occurs in the first 4-5 day of treatment.
To date no Italian guideline is available, but we believe
that it should be fundamental to establish a rational and
uniform approach to the management of acute GABHS
pharyngitis in all the country.
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